Bevacizumab Addition in Neoadjuvant Treatment Increases the Pathological Complete Response Rates in Patients with HER-2 Negative Breast Cancer Especially Triple Negative Breast Cancer: A Meta-Analysis

BACKGROUND: Neoadjuvant therapy is administered to breast cancer patients as an induction process before surgery or radiotherapy to reduce tumor size. Human epidermal growth factor receptor-2 (HER-2) negative breast cancer lacks effective standard target therapy. Bevacizumab has a controversial role...

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, Xuelei, Wang, Xiaoshan, Huang, Jingwen, Chen, Yingtai, Zhang, Jing, Zhang, Binglan, Shi, Changle, Liu, Lei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5006981/
https://www.ncbi.nlm.nih.gov/pubmed/27579484
http://dx.doi.org/10.1371/journal.pone.0160148

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5006981/
https://www.ncbi.nlm.nih.gov/pubmed/27579484
http://dx.doi.org/10.1371/journal.pone.0160148

Ejemplares similares